One of the highlights of Eli Lilly's third ... strength version of its drug. The launch of Mounjaro always raised the risk that it would cannibalise sales of Lilly's own GLP-1 agonist Trulicity ...
AGNC Investment Corp. Dep. Pfd. (Rep. 6.875% Cum. Redeem. Pfd. Series D 0.20% AGNC Investment Corp. Dep. Pfd. (Rep. 1/1000th Pfd. Series C) 0.31% AGNC Investment Corp ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback